Compare

Compare stocks side by side

Pick up to 3 companies to see where each one is stronger or weaker.

BIIBLLY

Biogen Inc.

BIIB · $252.20

55Fair

Eli Lilly and Company

LLY · $1273.46

70Good

Area by area

Overall Quant Score

How does it look overall? (out of 100)

BIIB

55/100

LLY

70/100

Quality

Is it a profitable, well-run business?

BIIB

3.1/10

LLY

9.4/10

Growth

Is the company growing?

BIIB

2.6/10

LLY

10.0/10

Valuation

Is the price reasonable? (higher = cheaper)

BIIB

7.1/10

LLY

3.4/10

Risk

How risky are the shares? (higher = lower risk)

BIIB

6.4/10

LLY

7.4/10

Momentum

Is the share price trending up?

BIIB

7.3/10

LLY

9.5/10

Financial strength

Is the balance sheet healthy?

BIIB

4.5/10

LLY

7.1/10

The balanced view

Model-generated

Biogen Inc.

This company has a mixed profile, with a positive price trend and a reasonable valuation, although its growth has been slow.

Leads on: valuation

Best feature: positive price trend (Trend alignment (50/200 SMA): 3/3)

Watch out: growth is slow or negative (Net income growth (FY): -20.8%)

Eli Lilly and Company

This company scores above average, with solid growth and a positive price trend, although its current valuation deserves attention.

Leads on: quality, growth, risk, momentum, financial strength

Best feature: solid growth (Revenue growth (FY): 44.7%)

Watch out: valuation may be demanding (DCF upside: -43.2%)

Different strengths suit different goals — a higher score in one area doesn’t make a stock the better choice for everyone.